No Benefit Seen From Adjuvant Celecoxib in ERBB2-Negative Breast Cancer
Disease-free survival did not improve with two years of celecoxib versus placebo in ERBB2-negative breast cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.